Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use

Mostrar otras versiones (1)

Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF). In the ensuing 20 years, this distinctive inodilator, which enhances cardiac...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp, Zoltán, Agostoni, Piergiuseppe, Alvarez, Julian, Bettex, Dominique, Bouchez, Stefan, Brito, Dulce, Černý, Vladimir, Comin-Colet, Josep, Crespo-Leiro, Marisa G., Delgado, Juan F., Édes, István, Eremenko, Alexander A., Farmakis, Dimitrios, Fedele, Francesco, Fonseca, Cândida, Fruhwald, Sonja, Girardis, Massimo, Guarracino, Fabio, Harjola, Veli-Pekka, Heringlake, Matthias, Herpain, Antoine, Heunks, Leo M. A., Husebye, Tryggve, Ivancan, Višnja, Karason, Kristjan, Kaul, Sundeep, Kivikko, Matti, Kubica, Janek, Masip, Josep, Matskeplishvili, Simon, Mebazaa, Alexandre, Nieminen, Markku S., Oliva, Fabrizio, Papp, Julius G., Parissis, John, Parkhomenko, Alexander, Põder, Pentti, Pölzl, Gerhard, Reinecke, Alexander, Ricksten, Sven-Erik, Riha, Hynek, Rudiger, Alain, Sarapohja, Toni, Schwinger, Robert H. G., Toller, Wolfgang, Tritapepe, Luigi, Tschöpe, Carsten, Wikström, Gerhard, von Lewinski, Dirk, Vrtovec, Bojan, Pollesello, Piero
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Journal of Cardiovascular Pharmacology 2020
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340234/
https://www.ncbi.nlm.nih.gov/pubmed/32639325
http://dx.doi.org/10.1097/FJC.0000000000000859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340234/
https://www.ncbi.nlm.nih.gov/pubmed/32639325
http://dx.doi.org/10.1097/FJC.0000000000000859

Ejemplares similares